


Leupeptin

Structure:



	Hemisulfate	Trifluoroacetate Salt	Hydrochloride
Molecular Formula	$C_{20}H_{38}N_6O_4 \cdot \frac{1}{2}H_2SO_4$	$C_{20}H_{38}N_6O_4 \cdot C_2HF_3O_2$	$C_{20}H_{38}N_6O_4 \cdot HCl$
Molecular Weight	475.6	540.6	463.0
CAS #	103476-89-7	147385-61-3	24125-16-4

Synonym: Acetyl-Leu-Leu-Arg-al

Physical Description: White to off-white powder

Solubility: Soluble in water (50 mg/ml-clear, faint yellow solution). Stock solutions of 10 mM in water are stable for 1 week at 4°C and 1 month if aliquoted and stored at -20°C. Stock solutions can then be diluted 1:100 to make a 100 uM working solution. Working solutions are stable for only a few hours.

Description: A modified tripeptide reversible protease inhibitor of trypsin-like proteases and some cysteine proteases¹² including endoproteinase Lys-C, kallikrein, papain, thrombin, cathepsin B⁶, cathepsins H and L¹⁴, trypsin, calpain¹³, trypsin⁸ and plasmin. Effective concentration is typically 10-100 uM. Little to no inhibition is seen against pepsin, cathepsins A and D and alpha-chymotrypsin. When adjusted for molarity, all three salt forms are equally effective; however, the hydrochloride salt is usually less invasive in biological settings.

Leupeptin, because of its aldehyde group, may act as a reducing agent and therefore interfere in protein determinations such as Lowry and, to a lesser extent, Bradford.⁹

Note: Leupeptin gives multiple peaks on HPLC due to equilibria among three forms in solution. Purity determined by HPLC should take into account the three main peaks.¹¹ Majority of contaminating peptide is racemized leupeptin.

The primary mechanism of inactivation is racemization of the L-arginal; the D-arginal form is totally inactive. If the aldehyde is oxidized but retains its L-configuration, the resulting compound does have some inhibitory activity.

Availability:

Catalog Number	Description	Size
151553	Leupeptin Hemisulfate	0.5 mg 1 mg 5 mg 25 mg 100 mg
195623	Leupeptin Trifluoroacetate salt	1 mg 5 mg 25 mg
195624	Leupeptin Hydrochloride	1 mg 5 mg 25 mg 100 mg

[Click Here for a list of other protease inhibitors offered by MP Biomedicals and general protease inhibitor information.](#)

References:

1. *Merck Index*, 12th Ed., No. 5483.

2. Aoyagi, T., *J. Antibiot.*, **v. 22**, 283 (1969).
3. Brass, L.F. and Shaltil, S.J., *J. Biol. Chem.*, **v. 263**, 5210 (1988).
4. Deutscher, M.P., "Maintaining protein stability." *Methods Enzymol.*, **v. 182**, 83-89 (1990).
5. Jazwinski, S.M., "Preparation of extracts from yeast." *Methods Enzymol.*, **v. 182**, 154-174 (1990).
6. Knight, C.G., *Biochem. J.*, **v. 189**, 447 (1980).
7. Kondo, S., et al., *Chem. Pharm. Bull.*, **v. 17**, 1869 (1969).
8. Kuramochi, H., et al., *J. Biochem.*, **v. 86**, 1403 (1979).
9. Maeda, K., et al., *J. Antibiot.*, **v. 24:6**, 402 (1971).
10. Powers, J.C. and Harper, J.W., *Proteinase Inhibitors: A Practical Approach* (Barrett, A.J. and Salvesen, G., eds.) Amsterdam, Elsevier, p. 244-245 (1989).
11. Saino, T., et al., *Chem. Pharm. Bull.*, **v. 30:7**, 2319 (1982).
12. Umezawa, H., *Methods Enzymol.*, **v. 45**, 678-683 (1976).
13. Zimmerman, U.-J.P. and Schlaepfer, W.W., *Biochemistry*, **v. 21**, 3977 (1982).
14. Zollner, H., *Handbook of Enzyme Inhibitors*, **2nd. Ed. Part B** (VCH Press, 1993), pp. 821-822.